Compare Gilead Sciences, Inc. (GILD) vs iShares Russell 2000 ETF (IWM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs iShares Russell 2000 ETF — how do they compare? Gilead Sciences, Inc. trades at $147.01 (market cap $182.40B), while iShares Russell 2000 ETF trades at $278.66 (market cap $77.70B). The key difference: Gilead Sciences, Inc. is far larger — about 2.3× iShares Russell 2000 ETF's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while iShares Russell 2000 ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and iShares Russell 2000 ETF for 83 Days on average.
| GILD | IWM | |
|---|---|---|
Market Cap | $182.40B | $77.70B |
Volume | 4,469,821 | 35,598,983 |
Sector | Health | — |
52-Week High | $155.80 | $305.06 |
52-Week Low | $116.74 | $229.13 |
Typical Hold Time | 111 Days | 83 Days |
Enterprise Value | $205.46B | — |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% with bullish technical signals and strong analyst support. Recent earnings beat expectations in three consecutive quarters, though Q2 showed a significant loss. The company maintains robust operating cash flow of $10.02B (2025) and expanded HIV prevention access through a major PAHO partnership. Valuation metrics show a P/E of 17.84 and P/S of 6.02, with revenue growth from $29.44B (2025) to projected $30.5B (2026).
Outlook remains positive with 65% analyst buy ratings and $151.57 consensus target, though risks include negative net income margin (-10.64%) and high debt levels. The stock offers dividend income ($0.82 upcoming) and pipeline catalysts in oncology/HIV, but investors should monitor earnings volatility and competitive pressures in biopharma.
IWM trades at $277.72, down 1.27% amid broader small-cap weakness. Technical indicators show a bearish trend with resistance at $278 and support at $275. The ETF faces headwinds from Federal Reserve rate hikes and underperformance relative to large-cap indices over the past decade. Recent news highlights concerns about small-cap risk premiums and competition from more selective small-cap funds.
The outlook remains cautious as rising interest rates pressure small-cap valuations. Opportunities exist for long-term investors seeking diversification from tech-heavy large caps, but near-term risks include economic sensitivity and narrow market breadth. The bearish technical setup suggests further downside potential unless macroeconomic conditions improve.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About iShares Russell 2000 ETF
The ETF is designed to track the performance of the securities and the stocks in the Russell 2000 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on IWM →
